“This platform launch marks a pivotal moment for inpatient mental health care,” said Todd Haedrich, CEO of LIO. “LIO represents a fundamental evolution of our capabilities, addressing the most ...

The Company's application to expand Flamingo-01 into Romania has been formally approved by European regulators, thus adding Romanian sites to the approximately 150 approved sites in Spain, France, ...

TAUNTON, U.K., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Corza Medical, a leading global manufacturer of surgical technologies and medical device components announced today the launch of its Biomedical ...

In August, ImmuneOnco announced that an abstract has been accepted for poster presentation at IASLC’s 2025 World Conference on Lung Cancer (September 6 th -9 th, 2025), which will provide updated ...

Pratteln, Switzerland, 13 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN) for the ...

This is the first ever autoimmunity study to evaluate a potential functional cure that targets the antigenic source – the origin of autoimmune disease; The Phase 1/2 study (up t ...

Jefferies, Piper Sandler and Guggenheim Securities are acting as joint active bookrunning managers for the offering. Raymond James, Wedbush PacGrow and H.C. Wainwright & Co. are acting as lead ...

Company reports $12.7 million in revenue in Q2’25, consisting primarily of $4.5 million in YCANTH ® revenue, net, reflecting sequential growth of 32.5% over Q1’25 and $8.0 million in milestone revenue ...

Under the revised operating plan and with the additional financing, cash and investments expected to provide runway into 2H 2028 (previously 2H 2027) and beyond anticipated primary endpoint readouts ...

Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights Emrosi™ net sales of $2.8 million generated in first full quarter on the market The Company ...

In May 2025, the Company reported additional long-term data from its nonhuman primate (“NHP”) study that demonstrated durable and consistent FVIII activity levels through approximately 19 months. Mean ...

New data confirm highly selective profile of cell-targeted lipid nanoparticle (ctLNP) and first-ever siRNA delivery to T cells in non-human primates • Lead siRNA candidates show potent knockdown of ...